Is TriSalus Life Sciences Inc. (TLSIW) overvalued? · rev $29.4M
TriSalus Life Sciences Inc. (TLSIW) common stock listed on NASDAQ.
This page asks whether TriSalus Life Sciences Inc. (TLSIW) looks expensive on cached numbers — not a short thesis.
Latest reported TLSIW revenue for 2024-12-31 was $29.4M. Net income was -$30.0M. Revenue was up 59.0% from 2023-12-31 to 2024-12-31. TLSIW currently screens at market cap $0.
TLSIW currently screens at market cap $0. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next TLSIW 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the TLSIW stock page for the full model, not this heading.
Not investment advice.